Pages that link to "Q39844789"
Jump to navigation
Jump to search
The following pages link to Complete androgen blockade for the treatment of prostate cancer (Q39844789):
Displaying 30 items.
- Crystal structure of human dehydroepiandrosterone sulphotransferase in complex with substrate (Q27638928) (← links)
- Clinical and economic considerations in the treatment of prostate cancer (Q33560832) (← links)
- Prostate Cancer Old Problems and New Approaches. Part III. Prevention and Treatment (Q34138145) (← links)
- 4-Methyl-3-oxo-4-aza-5α-androst-1-ene-17β-N-aryl-carboxamides: an approach to combined androgen blockade [5α-reductase inhibition with androgen receptor binding in vitro] (Q34432256) (← links)
- Daily dosing with flutamide or casodex exerts maximal antiandrogenic activity (Q34451919) (← links)
- Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer (Q34468524) (← links)
- Dehydroepiandrosterone: Is There a Role for Replacement? (Q35553087) (← links)
- P2-purinergic receptor agonists inhibit the growth of androgen-independent prostate carcinoma cells (Q35596450) (← links)
- Flutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in advanced prostatic cancer (Q36972786) (← links)
- Increased bone mineral density in patients with non-alcoholic steatohepatitis. (Q37358283) (← links)
- Blockade of testicular and adrenal androgens in prostate cancer treatment (Q37829637) (← links)
- Flutamide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic cancer (Q38679768) (← links)
- Development of androgen-independent tumor cells and their implication for the treatment of prostatic cancer (Q39668050) (← links)
- Combination therapy in stage C and D prostatic cancer: rationale and five year clinical experience (Q39697074) (← links)
- The enzyme and inhibitors of 4-ene-3-oxosteroid 5α-oxidoreductase (Q40483542) (← links)
- Complete androgen blockade as primary treatment for advanced metastatic cancer of the prostate (Q41206307) (← links)
- Ocular toxicity of Anandron in patients treated for prostatic cancer (Q41954517) (← links)
- Controversies in the management of advanced prostate cancer (Q42135671) (← links)
- Sexuality changes in prostate cancer patients receiving antihormonal therapy combining the antiandrogen flutamide with medical (LHRH agonist) or surgical castration (Q42213678) (← links)
- The effect of flutamide on basal and ACTH-stimulated plasma levels of adrenal androgens in patients with advanced prostate cancer (Q42502791) (← links)
- Long term treatment with luteinising hormone releasing hormone agonists and maintenance of serum testosterone to castration concentrations (Q43253182) (← links)
- Adult-onset acne: prevalence, impact, and management challenges (Q49228254) (← links)
- A case for synchronous reduction of testicular androgen, adrenal androgen and prolactin for the treatment of advanced carcinoma of the prostate (Q71988465) (← links)
- Inhibitory effects of medroxyprogesterone acetate (MPA) and the pure antiestrogen EM-219 on estrone (E1)-stimulated growth of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat (Q71989502) (← links)
- Prevention by dehydroepiandrosterone of the development of mammary carcinoma induced by 7,12-dimethylbenz(a)anthracene (DMBA) in the rat (Q72016594) (← links)
- Response to Flutamide Withdrawal in Advanced Prostate Cancer in Progression Under Combination Therapy (Q72090259) (← links)
- Cyproterone acetate monotherapy in advanced prostatic carcinoma (Q73553445) (← links)
- DHEA as physiological replacement therapy at menopause (Q77070593) (← links)
- The importance of antiandrogen in prostate cancer treatment (Q89521115) (← links)
- Systematically understanding the immunity leading to CRPC progression (Q90024077) (← links)